June 2019 Issue Table Of Contents

From The Editor

• Will What Happened With Product Promotion Be Replicated In Product Pricing?

Feature Articles

• The Whirlwind Rise Of Orchard Therapeutics
• Should Pharma Care About Digital Therapeutics?

Capitol Perspectives

• Fiscal And Monetary Policy Puts America At Risk

CEO Corner

• The Forgotten Piece Of The Opioid Epidemic — And How It Can Be Addressed

From Principles and Policy to Execution

• Should Healthcare Be Held To A Higher Standard?

Companies To Watch

• Synlogic

Patient Perspectives

• Embrace Your Inner Diva: Institutionalizing Patient-Centric Innovation

Industry Research

• Trends In Phase 4 CRO Selection Drivers

Inside The Industry

• Outsourcing Motivations Should Guide One’s Outsourcing Approach
• Analysis Of The Biosimilar Market As Herceptin Exclusivity Nears Its End
• Developing Cannabinoid Pharmaceuticals Amid The “Cannabusiness” Craze
• “New Science” Alleviates Economic Constraints
• State Of Boston’s Life Sciences Real Estate Market
• Making Sense Of New Accounting and Financial Reporting Changes

Industry Leader

• The Great Regulatory Catch-Up: Shortcuts To Compliance For Medical Devices Manufacturers
• 6 Tips For Contracting Or Seeking Funding From The Federal Government

Leadership Lessons

• Give Your Team A Break

Ask The Board

• How Do You Mitigate The Risks To Patient Safety And Data Integrity In Virtual Clinical Trials?
• Do You Think The Biopharma Industry Is Prepared For Brexit, And What Impact Will It Have On The Industry?
• How Are Life Science Leaders Preparing For A Potential Talent Shortage In The New Digital World?